Condition: Gastric Cancer (GC) · Adjuvant Chemotherapy · Stage 3 Cancer · Sponsor: Ruijin Hospital
This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.
This description comes directly from the study's public registry record.
Chenfei Zhou, MD, Ph.D · +86-21-64370045 · zcf12085@rjh.com.cn
Always discuss trial participation with your own doctor first.
| Yuebei People's Hospital | Shaoguan, Guandong, China | Not Yet Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Not Yet Recruiting |
| Renji Hospital | Shanghai, China | Not Yet Recruiting |
| Ruijin Hospital | Shanghai, China | Recruiting |
| Shanghai Tenth People's Hospital | Shanghai, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07366528